Discover how the FDA’s new guidance on Prescription Drug Use-Related Software (PDURS) can drive brand differentiation and commercial success in the pharmaceutical industry. https://ow.ly/Ic8v50SPo0T In our new thought leadership article, Manuel Jurado from The Dedham Group and Austin Speier and Steven L. from Click Therapeutics, Inc. explore the opportunities this guidance presents. Click the link in this post for the insights.
The Dedham Group
Business Consulting and Services
New York, NY 17,102 followers
Management and Strategic Consulting Services
About us
The Dedham Group is the premier US oncology & specialty therapeutics strategy consulting firm that combines deep clinical expertise in specialty disease areas, commercial & market access expertise and proprietary analytics to provide highly differentiated recommendations & strategic support to our clients in the pharmaceutical and biotech industry. Our work focuses on being highly data-driven and developing highly custom and integrated strategies in exciting areas of clinical innovation which span oncology, cell & gene therapy, immunology, neurology, rare diseases and precision medicine. We are deeply embedded with our clients which span senior leaders across sales & marketing, market access, distribution & patient services, pricing & contracting and channel strategy across marquee brands on the cutting edge of clinical innovation from many of the most admired companies. Our team is comprised of highly talented entrepreneurial, collaborative and creative leaders that are focused on insights development, storytelling and creating custom strategies & products for our strategic clients, maintaining the high quality & deep specialization expectations of a boutique firm. Our organization prides itself on being a merit-driven, team-based, high-performance culture where our people care greatly about their clients’ careers, the impact of their work and the overall well-being of their colleagues.
- Website
-
http://www.dedhamgroup.com
External link for The Dedham Group
- Industry
- Business Consulting and Services
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Consulting, Healthcare, and Research
Locations
-
Primary
1 Penn Plaza
Suite 2505
New York, NY 10119, US
Employees at The Dedham Group
Updates
-
Discover the power of PULSE Analytics' Payer Quality of Access Tool. https://ow.ly/cseN50Sy1M9 Evaluate coverage restrictions, regional targets, and competitive access to optimize your strategic planning. Ready to unlock actionable insights? Connect with us today!
-
Pharma companies can help patients access biomarker testing by providing resources on patient identification, available vendors, proof of eligibility, and ordering instructions. The Dedham Group’s Jennifer (Goldenberg) Klarer, M.Sc.Eng. and Hannah Baxter with MMIT (Managed Markets Insight & Technology)'s Carolyn Zele share tips for oncology manufacturers in Drug Channels: https://ow.ly/XBmY50RG2fe. #Pharma #PharmaManufacturers #MarketAccess #Oncology
-
Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/tg7E50RRF6Z #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies
As Sales of Weight Loss Drugs Skyrocket, the Insulin Market Falters | BioSpace
biospace.com
-
The Dedham Group’s Pooja Rana, MPH and Jennifer (Goldenberg) Klarer, M.Sc.Eng. write about the biggest challenges to cell and gene therapy reimbursement and how manufacturers can address them. https://ow.ly/sHxZ50SIzqc Read the article by visiting the link in this post.
-
The FDA’s guidance on Regulatory Considerations for Prescription Drug Use-Related Software (PDURS) opens up opportunities for brand differentiation and commercial success in pharma. https://ow.ly/VqV050SPoQF The Dedham Group’s Manuel Jurado, with Austin Speier and Steven L. of Click Therapeutics, Inc. write about how pharma manufacturers can prepare for PDURS guidance and capitalize on these opportunities. Read the article for more.
-
Discover unparalleled enterprise transformation with The Dedham Group. Our approach merges strategic insight with tailored solutions, navigating your enterprise's complexities. We understand your unique context to deliver actionable strategies aligned with your goals for lasting impact. Partner with us to transform your organization. https://ow.ly/T4Zp50S1bkJ
Enterprise Strategy - The Dedham Group
-
Navigate the complexities of clinical pathways with ease using PULSE Analytics. https://ow.ly/VWfc50Sy1JM Assess adoption, implementation, incentives, and access risks effortlessly. Gain insights into pathways affiliation, oncologist exposure, influencer identification, and more. Connect with us today!
-
The high cost and complex logistics of cell and gene therapies pose significant challenges for reimbursement, hindering patient access. https://ow.ly/sl1S50SIzJR Pooja Rana, MPH and Jennifer (Goldenberg) Klarer, M.Sc.Eng. of The Dedham Group write about how manufacturers must take strategic approaches to navigate these approaches. Click the link to the article in this post to learn more.
-
Creating a successful portfolio optimization strategy requires a nuanced understanding of market dynamics, technological innovations, and regulatory environments, writes Michael Hamlin. Here’s how to get started: https://ow.ly/xAe150RIXAu. #PortfolioOptimization #MarketDynamics #RegulatoryEnvironment #InvestmentStrategy #TechnologicalInnovations
The Portfolio Optimization Balancing Act: Keys to Improving Business Outcomes - The Dedham Group
https://dedhamgroup.com